Congenital hyperinsulinism is a condition that leads to excess insulin secretion due to defects in pancreatic beta cells. It can cause hypoglycemia in infants and children. Continuous exposure to low glucose levels due to congenital hyperinsulinism can cause seizures, brain damage, and other long-term health issues. Treatment options for congenital hyperinsulinism include oral diazoxide, oral somatostatin analogs, subtotal pancreatectomy, near-total pancreatectomy, and islet cell transplantation. The increasing awareness regarding early diagnosis and treatment of congenital hyperinsulinism is driving more patients to seek treatment options.

The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The rising awareness levels about congenital hyperinsulinism and availability of advanced treatment options are some of the major factors fueling the growth of the congenital hyperinsulinism treatment market. Various awareness campaigns by government and non-profit organizations are helping identify the symptoms of congenital hyperinsulinism at an early stage. This is enabling timely intervention and management of the condition. Furthermore, development of novel drugs and technologies for congenital hyperinsulinism treatment is also supporting the market growth. For instance, oral diazoxide, a benzothiadiazine derivative, was introduced in the 1960s for the treatment of congenital hyperinsulinism. Continued focus on R&D of improved treatment solutions is expected to present lucrative growth opportunities for players in this market over the forecast period.

Segment Analysis
The global congenital hyperinsulinism treatment market is dominated by the drug segment. The drug segment accounts for a larger revenue share owing to the increasing adoption of pharmacological therapy such as diazoxide and octreotide for the treatment of congenital hyperinsulinism. However, the surgery segment is expected to grow significantly during the forecast period due to the rising number of surgical treatment procedures including partial pancreatectomy being performed for severe forms of congenital hyperinsulinism.

Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth rate during the forecast period.

Regional Analysis: North America is currently dominating the market and is expected to continue its dominance in the global market owing to the well-established healthcare infrastructure and rising incidence of congenital hyperinsulinism in the region.

Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices. The market players are focusing on new product launches, partnerships, and regional expansion to gain more market share.

 

Get more insights on this topic:
https://www.dailyprbulletin.com/congenital-hyperinsulinism-treatment-market-share/

Check below trending articles related to this topic:
https://shoutingstars.com/the-rising-future-of-hydrogen-an-eco-friendly-fuel-for-a-greener-tomorrow

Explore more trending article related to this topic:
https://shoutingstars.com/pd-1-and-pd-l1-inhibitors-a-promising-cancer-immunotherapy